Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Sir Run Run Shaw Hospital is the lead sponsor of 45 current clinical trials in our China register. 24 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Capecitabine, Oxaliplatin and INeo-Vac-R01. The most-studied condition is Digestive System Neoplasms.

ClinicalTrials.gov trials by status

Recruiting2453%
Not yet open1329%
Active, closed613%
By invitation24%

Trials by phase

Not applicable2044%
Phase 21329%
Observational511%
Phase 137%
Phase 324%
Phase EARLY_PHASE112%
Phase 412%

Clinical trials sponsored by Sir Run Run Shaw Hospital

45 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms NCT06026800 · ClinicalTrials.gov ↗ · Digestive System Neoplasms Drug: INeo-Vac-R01	Phase 1	Recruiting	2023-09	China
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms NCT06026774 · ClinicalTrials.gov ↗ · Digestive System Neoplasms Drug: INeo-Vac-R01	Phase 1	Recruiting	2023-09	China
Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer NCT06167967 · ClinicalTrials.gov ↗ · Colorectal Cancer	Not applicable	Recruiting	2024-04	China
Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients NCT07574502 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)	Not applicable	Recruiting	2026-06	China
The Hi-tACS on Cognitive Function in Patients With Schizophrenia NCT06470516 · ClinicalTrials.gov ↗ · Schizophrenia	Not applicable	Recruiting	2024-04	China
Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion NCT06633809 · ClinicalTrials.gov ↗ · Stroke, Acute, Cerebrovascular Disorders, Brain Diseases	Observational	Recruiting	2021-11	China
Group-based IMPROVE Therapy for Problematic Internet Use in University Students NCT07434778 · ClinicalTrials.gov ↗ · Problematic Internet Use	Not applicable	Recruiting	2026-03	China
Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study NCT06996665 · ClinicalTrials.gov ↗ · Respiratory Failure	Not applicable	Recruiting	2025-06	China
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer NCT07068763 · ClinicalTrials.gov ↗ · Rectal Cancer Drug: Capecitabine	Phase 2	Recruiting	2025-10	China
Electroacupuncture at ST36 for Reducing Postoperative Inflammation After Cardiac Surgery With Cardiopulmonary Bypass NCT07795112 · ClinicalTrials.gov ↗ · Systemic Inflammatory Response Syndrome (SIRS), Cardiac Surgical Procedures, Postoperative Complications (Cardiopulmonary)	Not applicable	Recruiting	2026-09	China
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma NCT06266832 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma Drugs: Adebrelimab, Capecitabine, Oxaliplatin	Phase 2	Recruiting	2024-01	China
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE NCT07268560 · ClinicalTrials.gov ↗ · Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)	Observational	Recruiting	2025-12	China
Effectiveness of DITM Versus IMT in COPD Patients NCT06958666 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease)	Not applicable	Recruiting	2025-06	China
Transcutaneous Auricular Vagus Nerve Stimulation for Preventing Acute Kidney Injury in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass NCT07549243 · ClinicalTrials.gov ↗ · Acute Kidney Injury, Cardiac Surgery, Cardiopulmonary Bypass	Not applicable	Recruiting	2026-04	China
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma NCT07243691 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: Tislelizumab	Not applicable	Recruiting	2025-12	China
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma NCT06825546 · ClinicalTrials.gov ↗ · Advanced Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	2025-04	China
The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy NCT05035108 · ClinicalTrials.gov ↗ · Hepatoma Resectable	Phase EARLY_PHASE1	Recruiting	2021-09	China
Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion NCT07016854 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic	Not applicable	Recruiting	2025-06	China
Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule NCT07508618 · ClinicalTrials.gov ↗ · Persistent Atrial Fibrillation	Phase 4	Recruiting	2026-02	China
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma NCT05752136 · ClinicalTrials.gov ↗ · Rectal Cancer Drug: Envafolimab	Phase 3	Recruiting	2023-04	China
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma NCT07105852 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Drug: Sacituzumab tirumotecan	Phase 2	Recruiting	2025-07	China
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer NCT05972655 · ClinicalTrials.gov ↗ · Low Rectal Cancer Drugs: Capecitabine, Oxaliplatin	Phase 2	Recruiting	2023-08	China
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms NCT06019702 · ClinicalTrials.gov ↗ · Digestive System Neoplasms	Phase 1	Recruiting	2023-09	China
Smoking Cessation Program With CBT and Mindfulness Audio Support: A Randomized Controlled Trial NCT06901713 · ClinicalTrials.gov ↗ · Smoking Cessation; Tobacco Dependence	Not applicable	Recruiting	2024-10	China
Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer NCT06596343 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Postoperative Adjuvant Therapy	Phase 2	Not yet open	2024-10	China
Effectiveness of Robotic Surgery for Right Colon Cancer NCT06421974 · ClinicalTrials.gov ↗ · Colon Cancer, Robotic Surgery	Not applicable	Not yet open	2024-06	China
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support NCT07751003 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD, Hypercapnia	Not applicable	Not yet open	2027-08	China
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer NCT06872606 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma Drugs: Bevacizumab, Oxaliplatin, Pucotenlimab	Phase 2	Not yet open	2025-04	China
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC NCT06699459 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma Drugs: Capecitabine, Irinotecan liposome	Phase 2	Not yet open	2024-11	China
PTSD Risk Prediction Model for EICU Survivors NCT07747415 · ClinicalTrials.gov ↗ · Post-traumatic Stress Disorder (PTSD)	Observational	Not yet open	2026-08	China
Decision-making and Optimization of Ventilatory Support for AECOPD Patients NCT07508943 · ClinicalTrials.gov ↗ · Acute Exacerbation of Chronic Obstructive Pulmonary Disease	Observational	Not yet open	2026-03	China
Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery NCT07631910 · ClinicalTrials.gov ↗ · Nausea and Vomiting, Postoperative Drug: Dexamethasone	Not applicable	Not yet open	2026-07	China
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07393477 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC	Phase 2	Not yet open	2026-02	China
Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins NCT07445425 · ClinicalTrials.gov ↗ · Varicose Veins of Lower Limb	Not applicable	Not yet open	2026-03	China
Cognitive Behavioral Therapy for Mobile Phone Addiction in Hospitalized Patients NCT07457658 · ClinicalTrials.gov ↗ · Problematic Use of Mobile Phones	Not applicable	Not yet open	2026-06	China
Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study NCT06594692 · ClinicalTrials.gov ↗ · Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer	Phase 2	Not yet open	2024-10	China
The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC NCT06895369 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck Drug: Pucotenlimab	Phase 2	Not yet open	2025-05	China
Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Symptoms and High Stroke Risk NCT07453940 · ClinicalTrials.gov ↗ · ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, PFA Ablation and LAAC Procedures	Not applicable	By invitation	2026-05	China
Catheter Ablation for Atrial Fibrillation in Non-Fluoroscopic Lab NCT06719921 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Not applicable	By invitation	2025-04	China
Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules NCT07638228 · ClinicalTrials.gov ↗ · Malignant Pulmonary Nodules, Lung Cancer	Not applicable	Active, closed	2025-09	China
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) NCT07160647 · ClinicalTrials.gov ↗ · dMMR/MSI-H-type Rectal Adenocarcinoma	Phase 2	Active, closed	2025-08	China
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer NCT07512674 · ClinicalTrials.gov ↗ · Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis	Phase 2	Active, closed	2026-02	China
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer NCT06507371 · ClinicalTrials.gov ↗ · Rectal Cancer Drugs: Capecitabine, Oxaliplatin	Phase 3	Active, closed	2024-07	China
Home Oscillatory Positive Expiratory Pressure - Aerobic Exercise Rehabilitation Study NCT06970054 · ClinicalTrials.gov ↗ · COPD, AECOPD	Not applicable	Active, closed	2026-03	China
AI-Powered Sound Analysis for COPD Screening NCT07457073 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD)	Observational	Active, closed	2026-02	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Sir Run Run Shaw Hospital trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Capecitabine5 Oxaliplatin4 INeo-Vac-R012 Pucotenlimab2 Adebrelimab1 Bevacizumab1 Dexamethasone1 Envafolimab1 Irinotecan liposome1 Sacituzumab tirumotecan1 Tislelizumab1 Trifluridine/tipiracil hydrochloride1

Conditions in Sir Run Run Shaw Hospital trials

57 conditions

Digestive System Neoplasms3Rectal Cancer3 COPD (Chronic Obstructive Pulmonary Disease)2Rectal Adenocarcinoma2Locally Advanced Colorectal Cancer1Postoperative Adjuvant Therapy1Malignant Pulmonary Nodules1Lung Cancer1 Colon Cancer1Robotic Surgery1dMMR/MSI-H-type Rectal Adenocarcinoma1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis1Colorectal Cancer1Acute Exacerbation of COPD1Hypercapnia1Biliary Tract Carcinoma1Colorectal Cancer (CRC)1Post-traumatic Stress Disorder (PTSD)1Schizophrenia1 Stroke, Acute1 Cerebrovascular Disorders1 Brain Diseases1Central Nervous System Diseases1Acute Exacerbation of Chronic Obstructive Pulmonary Disease1

By trial register

Register	Trials	Recruiting
Clinical trials in China	45	24

A trial with sites in more than one country appears in each of those registers.

Questions about Sir Run Run Shaw Hospital trials

How many clinical trials does Sir Run Run Shaw Hospital sponsor?

Sir Run Run Shaw Hospital is the lead sponsor of 45 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sir Run Run Shaw Hospital trials recruiting?

Yes. 24 of its 45 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sir Run Run Shaw Hospital testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Capecitabine (5), Oxaliplatin (4), INeo-Vac-R01 (2), Pucotenlimab (2) and Adebrelimab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Sir Run Run Shaw Hospital clinical trials